Melanie Yvonne White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melanie Yvonne White has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Stuart J. Cordwell
Discipline of Pathology, School of Medical Sciences, The University of Sydney, Sydney 2006, Australia
24 shared publications - Brett D. Hambly
The University of Sydney
10 shared publications Alistair V. G. Edwards
Institut for Biokemi og Molekylær Biologi
5 shared publications- Rebekah L. Gundry
University of Nebraska Medical Center, Omaha, NE, United States of America
4 shared publications Adrian S. Tchen
School of Medical Sciences (Discipline of Pathology), The University of Sydney, Sydney, Australia
3 shared publicationsBenjamin L. Parker
Department of Biochemistry and Molecular Biology University of Southern Denmark Campusvej 55 5230 Odense M Denmark
3 shared publications
Latest Publications
- 25 May 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (6) , 526-540
Consensus statement on mass spectrometry-based proteomic analysis of cardiac tissue
Mass spectrometry-based cardiac proteomics provides direct molecular insight into cardiac physiology and disease. While plasma proteomics has advanced biomarker discovery, the analysis of cardiac tissue is essential for mechanistic understanding and therapeutic target identification; however, proteomic investigation of cardiac tissue faces unique challenges, including limited sample availability, regional heterogeneity, variability in collection and processing, and inconsistent reporting practices that hinder reproducibility and data integration. Here, we provide a practical framework for designing and conducting mass spectrometry-based proteomic studies of cardiac tissue and primary cardiac cells. We outline best practices and key considerations for sample handling, experimental design, data acquisition, quality control and statistical analysis. This guideline aims to support cardiac researchers in generating robust and reproducible proteomics datasets that advance our understanding of cardiac biology in both physiological and pathological contexts.
- 25 May 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (6) , 526-540
Consensus statement on mass spectrometry-based proteomic analysis of cardiac tissue
Mass spectrometry-based cardiac proteomics provides direct molecular insight into cardiac physiology and disease. While plasma proteomics has advanced biomarker discovery, the analysis of cardiac tissue is essential for mechanistic understanding and therapeutic target identification; however, proteomic investigation of cardiac tissue faces unique challenges, including limited sample availability, regional heterogeneity, variability in collection and processing, and inconsistent reporting practices that hinder reproducibility and data integration. Here, we provide a practical framework for designing and conducting mass spectrometry-based proteomic studies of cardiac tissue and primary cardiac cells. We outline best practices and key considerations for sample handling, experimental design, data acquisition, quality control and statistical analysis. This guideline aims to support cardiac researchers in generating robust and reproducible proteomics datasets that advance our understanding of cardiac biology in both physiological and pathological contexts.
- Open Access
- 1 April 2019
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 18 (4) , 715-734
Proteomics Reveals Multiple Phenotypes Associated with N-linked Glycosylation in Campylobacter jejuni
- 1 April 2019
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 18 (4) , 715-734
Open AccessProteomics Reveals Multiple Phenotypes Associated with N-linked Glycosylation in Campylobacter jejuni
- Open Access
- 14 September 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (12) , 4239-4255
Human macrophage cathepsin β‐mediated C‐terminal cleavage of apolipoprotein α‐I at Ser 228 severely impairs antiatherogenic capacity
Apolipoprotein α‐I (apoA‐I) is themajor component of HDLandcentral to the ability of HDLto stimulate ATP‐binding cassette transporter A1 (ABCA1)‐dependent, antiatherogenic export of cholesterol from macrophage foam cells, a key player in the pathology of atherosclerosis. Cell‐mediated modifications of apoA‐I, such as chlorination, nitration, oxidation, and proteolysis, can impair its antiatherogenic function, although it is unknown whether macrophages themselves contribute to such modifications. To investigate this, human monocyte‐derived macrophages (HMDMs) were incubated with human apoA‐I under conditions used to induce cholesterol export. Two‐dimensional gel electrophoresis and Western blot analysis identified that apoA‐I is cleaved (~20–80%) by HMDMs in a time‐dependent manner, generating apoA‐I of lower MW and isoelectric point. Mass spectrometry analysis identified a novel C‐terminal cleavage site of apoA‐I between Ser 228 ‐Phe 229 . Recombinant apoA‐I truncated at Ser 228 demonstrated profound loss of capacity to solubilize lipid and to promoteABCA1‐dependent cholesterol efflux. Protease inhibitors, small interfering RNA knockdown in HMDMs, mass spectrometry analysis, and cathepsin B activity assays identified secreted cathepsin B as responsible for apoA‐I cleavage at Ser 228 . Importantly, C‐terminal cleavage of apoA‐I was also detected in human carotid plaque. Cleavage at Ser 228 is a novel, functionally important post‐translationalmodification of apoA‐Imediated byHMDMsthat limits the antiatherogenic properties of apoA‐I.—Dinnes, D. L.M., White, M. Y., Kockx, M., Traini, M., Hsieh, V., Kim, M.‐J., Hou, L., Jessup, W., Rye, K.‐A., Thaysen‐Andersen, M., Cordwell, S. J., Kritharides, L. Human macrophage cathepsin B‐mediated C‐terminal cleavage of apolipoprotein A‐I at Ser 228 severely impairs antiatherogenic capacity. FASEB J. 30, 4239–4255 (2016). www.fasebj.org
- 14 September 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (12) , 4239-4255
Open AccessHuman macrophage cathepsin β‐mediated C‐terminal cleavage of apolipoprotein α‐I at Ser 228 severely impairs antiatherogenic capacity
Apolipoprotein α‐I (apoA‐I) is themajor component of HDLandcentral to the ability of HDLto stimulate ATP‐binding cassette transporter A1 (ABCA1)‐dependent, antiatherogenic export of cholesterol from macrophage foam cells, a key player in the pathology of atherosclerosis. Cell‐mediated modifications of apoA‐I, such as chlorination, nitration, oxidation, and proteolysis, can impair its antiatherogenic function, although it is unknown whether macrophages themselves contribute to such modifications. To investigate this, human monocyte‐derived macrophages (HMDMs) were incubated with human apoA‐I under conditions used to induce cholesterol export. Two‐dimensional gel electrophoresis and Western blot analysis identified that apoA‐I is cleaved (~20–80%) by HMDMs in a time‐dependent manner, generating apoA‐I of lower MW and isoelectric point. Mass spectrometry analysis identified a novel C‐terminal cleavage site of apoA‐I between Ser 228 ‐Phe 229 . Recombinant apoA‐I truncated at Ser 228 demonstrated profound loss of capacity to solubilize lipid and to promoteABCA1‐dependent cholesterol efflux. Protease inhibitors, small interfering RNA knockdown in HMDMs, mass spectrometry analysis, and cathepsin B activity assays identified secreted cathepsin B as responsible for apoA‐I cleavage at Ser 228 . Importantly, C‐terminal cleavage of apoA‐I was also detected in human carotid plaque. Cleavage at Ser 228 is a novel, functionally important post‐translationalmodification of apoA‐Imediated byHMDMsthat limits the antiatherogenic properties of apoA‐I.—Dinnes, D. L.M., White, M. Y., Kockx, M., Traini, M., Hsieh, V., Kim, M.‐J., Hou, L., Jessup, W., Rye, K.‐A., Thaysen‐Andersen, M., Cordwell, S. J., Kritharides, L. Human macrophage cathepsin B‐mediated C‐terminal cleavage of apolipoprotein A‐I at Ser 228 severely impairs antiatherogenic capacity. FASEB J. 30, 4239–4255 (2016). www.fasebj.org
- Open Access
- 20 April 2016
- Published by Wiley in Aging Cell
- Vol. 15 (4) , 706-715
Ultrastructure of the liver microcirculation influences hepatic and systemic insulin activity and provides a mechanism for age‐related insulin resistance
While age‐related insulin resistance and hyperinsulinemia are usually considered to be secondary to changes in muscle, the liver also plays a key role in whole‐body insulin handling and its role in age‐related changes in insulin homeostasis is largely unknown. Here, we show that patent pores called ‘fenestrations’ are essential for insulin transfer across the liver sinusoidal endothelium and that age‐related loss of fenestrations causes an impaired insulin clearance and hyperinsulinemia, induces hepatic insulin resistance, impairs hepatic insulin signaling, and deranges glucose homeostasis. To further define the role of fenestrations in hepatic insulin signaling without any of the long‐term adaptive responses that occur with aging, we induced acute defenestration using poloxamer 407 (P407), and this replicated many of the age‐related changes in hepatic glucose and insulin handling. Loss of fenestrations in the liver sinusoidal endothelium is a hallmark of aging that has previously been shown to cause deficits in hepatic drug and lipoprotein metabolism and now insulin. Liver defenestration thus provides a new mechanism that potentially contributes to age‐related insulin resistance.
- 20 April 2016
- Published by Wiley in Aging Cell
- Vol. 15 (4) , 706-715
Open AccessUltrastructure of the liver microcirculation influences hepatic and systemic insulin activity and provides a mechanism for age‐related insulin resistance
While age‐related insulin resistance and hyperinsulinemia are usually considered to be secondary to changes in muscle, the liver also plays a key role in whole‐body insulin handling and its role in age‐related changes in insulin homeostasis is largely unknown. Here, we show that patent pores called ‘fenestrations’ are essential for insulin transfer across the liver sinusoidal endothelium and that age‐related loss of fenestrations causes an impaired insulin clearance and hyperinsulinemia, induces hepatic insulin resistance, impairs hepatic insulin signaling, and deranges glucose homeostasis. To further define the role of fenestrations in hepatic insulin signaling without any of the long‐term adaptive responses that occur with aging, we induced acute defenestration using poloxamer 407 (P407), and this replicated many of the age‐related changes in hepatic glucose and insulin handling. Loss of fenestrations in the liver sinusoidal endothelium is a hallmark of aging that has previously been shown to cause deficits in hepatic drug and lipoprotein metabolism and now insulin. Liver defenestration thus provides a new mechanism that potentially contributes to age‐related insulin resistance.
- Open Access
- 1 March 2015
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 14 (3) , 609-620
Global Analysis of Myocardial Peptides Containing Cysteines With Irreversible Sulfinic and Sulfonic Acid Post-Translational Modifications
- 1 March 2015
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 14 (3) , 609-620
Open AccessGlobal Analysis of Myocardial Peptides Containing Cysteines With Irreversible Sulfinic and Sulfonic Acid Post-Translational Modifications
- Open Access
- 1 December 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (49) , 33875
Structural basis for phosphorylation and lysine acetylation cross-talk in a kinase motif associated with myocardial ischemia and cardioprotection.
- 1 December 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (49) , 33875
Open AccessStructural basis for phosphorylation and lysine acetylation cross-talk in a kinase motif associated with myocardial ischemia and cardioprotection.
- Open Access
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (37) , 25890-25906
Structural Basis for Phosphorylation and Lysine Acetylation Cross-talk in a Kinase Motif Associated with Myocardial Ischemia and Cardioprotection
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (37) , 25890-25906
Open AccessStructural Basis for Phosphorylation and Lysine Acetylation Cross-talk in a Kinase Motif Associated with Myocardial Ischemia and Cardioprotection
- 24 June 2014
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 8 (7-8) , 506-521
The role of post‐translational modifications in acute and chronic cardiovascular disease
Cardiovascular disease (CVD) in one of the leading causes of mortality and morbidity worldwide, accounting for both primary diseases of the heart and vasculature and arising as a co‐morbidity with numerous pathologies, including type 2 diabetes mellitus (T2DM). There has been significant emphasis on the role of the genome in CVD, aiding in the definition of ‘at‐risk’ patients. The extent of disease penetrance however, can be influenced by environmental factors that are not detectable by investigating the genome alone. By targeting the transcriptome in response to CVD, the interplay between genome and environment is more apparent, however this implies the level of protein expression without reference to proteolytic turnover, or potentially more importantly, without defining the role of PTMs in the development of disease. Here, we discuss the role of both brief and irreversible PTMs in the setting of myocardial ischemia/reperfusion injury. Key proteins involved in calcium regulation have been observed as differentially modified by phosphorylation/O‐GlcNAcylation or phosphorylation/redox modifications, with the level of interplay dependent on the physiological or pathophysiological state. The ability to modify crucial sites to produce the desired functional output is modulated by the presence of other PTMs as exemplified in the T2DM heart, where hyperglycemia results in aberrant O‐GlcNAcylation and advanced glycation end products. By using the signalling events predicted to be critical to post‐conditioning, an intervention with great promise for the cardioprotection of the ischemia/reperfusion injured heart, as an example, we discuss the level of PTMs and their interplay. The inability of post‐conditioning to protect the diabetic heart may be regulated by aberrant PTMs influencing those sites necessary for protection.
- 24 June 2014
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 8 (7-8) , 506-521
The role of post‐translational modifications in acute and chronic cardiovascular disease
Cardiovascular disease (CVD) in one of the leading causes of mortality and morbidity worldwide, accounting for both primary diseases of the heart and vasculature and arising as a co‐morbidity with numerous pathologies, including type 2 diabetes mellitus (T2DM). There has been significant emphasis on the role of the genome in CVD, aiding in the definition of ‘at‐risk’ patients. The extent of disease penetrance however, can be influenced by environmental factors that are not detectable by investigating the genome alone. By targeting the transcriptome in response to CVD, the interplay between genome and environment is more apparent, however this implies the level of protein expression without reference to proteolytic turnover, or potentially more importantly, without defining the role of PTMs in the development of disease. Here, we discuss the role of both brief and irreversible PTMs in the setting of myocardial ischemia/reperfusion injury. Key proteins involved in calcium regulation have been observed as differentially modified by phosphorylation/O‐GlcNAcylation or phosphorylation/redox modifications, with the level of interplay dependent on the physiological or pathophysiological state. The ability to modify crucial sites to produce the desired functional output is modulated by the presence of other PTMs as exemplified in the T2DM heart, where hyperglycemia results in aberrant O‐GlcNAcylation and advanced glycation end products. By using the signalling events predicted to be critical to post‐conditioning, an intervention with great promise for the cardioprotection of the ischemia/reperfusion injured heart, as an example, we discuss the level of PTMs and their interplay. The inability of post‐conditioning to protect the diabetic heart may be regulated by aberrant PTMs influencing those sites necessary for protection.